PURPOSE: EphA2 receptor tyrosine kinase is frequently overexpressed and functionally altered in a variety of human cancers. The study aimed to assess EphA2 expression and to explore its roles in squamous-cell carcinoma of the head and neck (SCCHN). METHODS: EphA2 expression in 98 primary SCCHN tissue specimens was analyzed by immunohistochemistry and correlated with clinicopathological parameters. Additionally, 13 paired SCCHN tissues and 6 SCCHN cell lines were evaluated for EphA2 expression by RT-PCR and immunoblotting. RESULTS: EphA2 overexpressed in SCCHN tissues and SCCHN cell lines. More importantly, high EphA2 expression was significantly associated with tumor site, T classification, clinical stage, recurrence, and lymph node metastasis, respectively. Patients with high EphA2 expression had both poorer disease-free survival and overall survival than patients with low EphA2 expression. Multivariate Cox regression analysis revealed that EphA2 overexpression was an independent prognostic factor for patients with SCCHN. CONCLUSIONS: These findings suggested that EphA2 may contribute to SCCHN progression and represent a novel prognostic indicator for patients with SCCHN.
PURPOSE:EphA2 receptor tyrosine kinase is frequently overexpressed and functionally altered in a variety of humancancers. The study aimed to assess EphA2 expression and to explore its roles in squamous-cell carcinoma of the head and neck (SCCHN). METHODS:EphA2 expression in 98 primary SCCHN tissue specimens was analyzed by immunohistochemistry and correlated with clinicopathological parameters. Additionally, 13 paired SCCHN tissues and 6 SCCHN cell lines were evaluated for EphA2 expression by RT-PCR and immunoblotting. RESULTS:EphA2 overexpressed in SCCHN tissues and SCCHN cell lines. More importantly, high EphA2 expression was significantly associated with tumor site, T classification, clinical stage, recurrence, and lymph node metastasis, respectively. Patients with high EphA2 expression had both poorer disease-free survival and overall survival than patients with low EphA2 expression. Multivariate Cox regression analysis revealed that EphA2 overexpression was an independent prognostic factor for patients with SCCHN. CONCLUSIONS: These findings suggested that EphA2 may contribute to SCCHN progression and represent a novel prognostic indicator for patients with SCCHN.
Authors: Madhu Macrae; Richard M Neve; Pablo Rodriguez-Viciana; Christopher Haqq; Jennifer Yeh; Chira Chen; Joe W Gray; Frank McCormick Journal: Cancer Cell Date: 2005-08 Impact factor: 31.743
Authors: Shaji Abraham; Deborah W Knapp; Liang Cheng; Paul W Snyder; Suresh K Mittal; Dinesh S Bangari; Michael Kinch; Lan Wu; Jay Dhariwal; Sulma I Mohammed Journal: Clin Cancer Res Date: 2006-01-15 Impact factor: 12.531
Authors: Christopher J Herrem; Tomohide Tatsumi; Kathleen S Olson; Keisuke Shirai; James H Finke; Ronald M Bukowski; Ming Zhou; Amy L Richmond; Ithaar Derweesh; Michael S Kinch; Walter J Storkus Journal: Clin Cancer Res Date: 2005-01-01 Impact factor: 12.531
Authors: Dana M Brantley-Sieders; Guanglei Zhuang; Donna Hicks; Wei Bin Fang; Yoonha Hwang; Justin M M Cates; Karen Coffman; Dowdy Jackson; Elizabeth Bruckheimer; Rebecca S Muraoka-Cook; Jin Chen Journal: J Clin Invest Date: 2008-01 Impact factor: 14.808
Authors: Aparna A Kamat; Donna Coffey; William M Merritt; Elizabeth Nugent; Diana Urbauer; Yvonne G Lin; Creighton Edwards; Russell Broaddus; Robert L Coleman; Anil K Sood Journal: Cancer Date: 2009-06-15 Impact factor: 6.860
Authors: Chunhua Lu; Mian M K Shahzad; Hua Wang; Charles N Landen; Seung W Kim; Julie Allen; Alpa M Nick; Nicholas Jennings; Michael S Kinch; Menashe Bar-Eli; Anil K Sood Journal: Cancer Biol Ther Date: 2008-04-19 Impact factor: 4.742
Authors: Marieta I Toma; Kati Erdmann; Michael Diezel; Matthias Meinhardt; Stefan Zastrow; Susanne Fuessel; Manfred P Wirth; Gustavo B Baretton Journal: PLoS One Date: 2014-07-15 Impact factor: 3.240